These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37363992)

  • 1. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Oaknin A; Pothuri B; Gilbert L; Sabatier R; Brown J; Ghamande S; Mathews C; O'Malley DM; Kristeleit R; Boni V; Gravina A; Banerjee S; Miller R; Pikiel J; Mirza MR; Dewal N; Antony G; Dong Y; Zografos E; Veneris J; Tinker AV
    Clin Cancer Res; 2023 Nov; 29(22):4564-4574. PubMed ID: 37363992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
    Powell MA; Bjørge L; Willmott L; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Gropp-Meier M; Stuckey A; Boere I; Gold MA; Segev Y; Gill SE; Gennigens C; Sebastianelli A; Shahin MS; Pothuri B; Monk BJ; Buscema J; Coleman RL; Slomovitz BM; Ring KL; Herzog TJ; Balas MM; Grimshaw M; Stevens S; Lai DW; McCourt C; Mirza MR
    Ann Oncol; 2024 Aug; 35(8):728-738. PubMed ID: 38866180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
    Berton D; Pautier P; Lorusso D; Gennigens C; Gladieff L; Kryzhanivska A; Bowman J; Tian C; Cornfeld M; Van Gorp T
    Gynecol Oncol; 2024 Jul; 186():191-198. PubMed ID: 38824752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
    Mathews C; Lorusso D; Coleman RL; Boklage S; Garside J
    Oncologist; 2022 Dec; 27(12):1058-1066. PubMed ID: 36124638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
    Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
    J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dostarlimab for the treatment of advanced endometrial cancer.
    Redondo A; Gallego A; Mendiola M
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 19. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.